Ensuring predictability for COVID-19 clinical trials and proposal for clinical trials records retention: Notice to stakeholders

The purpose of this notice is to advise stakeholders that Health Canada is proposing to: maintain the flexibilities and regulatory oversight provided by the Interim order respecting clinical trials for medical devices and drugs relating to COVID-19 until at least the fall of 2021, and bring forward regulatory amendments that would allow the flexibilities under the Interim Order to continue after the fall of 2021.

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 22:11 (UTC)
Created	April 17, 2026, 22:11 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2020-12-10 00:00:00
open_canada_keywords	{"fr": ["COVID-19", "pandémie", "prévisibilité", "surveillance réglementaire", "essais cliniques COVID-19", "essais cliniques", "dispositifs médicaux et médicaments", "avis aux parties prenantes", "arrêté d'urgence", "modifications réglementaires"], "en": ["COVID-19", "pandemic", "predictability", "regulatory oversight", "COVID-19 clinical trials", "clinical trials", "medical devices and drugs", "notice to stakeholders", "Interim Order", "regulatory amendments"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Garantir la prévisibilité des essais cliniques relatifs à la COVID-19 et proposition concernant la conservation des registres d’essais cliniques : Avis aux intervenants
update_frequency	as_needed